Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.

Clin Pharmacol Ther 2003 Mar;73(3):170-7

Lilly Laboratory for Clinical Research, Indiana University Hospital and Outpatient Center, 550 N. University Road, Indianapolis, IN 46202-5250, USA.

Background And Objectives: Duloxetine, a potent dual reuptake inhibitor of serotonin and norepinephrine currently undergoing clinical investigation for treatment of depression and stress urinary incontinence, has the potential to act as both a substrate and an inhibitor of cytochrome P4502D6 (CYP2D6). Our objectives were to determine the effect of duloxetine on the pharmacokinetics of desipramine, a tricyclic antidepressant metabolized by CYP2D6 (study 1), and the effect of paroxetine, a potent CYP2D6 inhibitor, on duloxetine pharmacokinetics (study 2).

Methods: Subjects were healthy men and women between 21 and 63 years old. All subjects were genotypically CYP2D6 extensive metabolizers. In study 1, 50 mg of desipramine was administered as a single dose alone and in the presence of steady-state duloxetine 60 mg twice daily. In study 2, steady-state pharmacokinetics of duloxetine 40 mg once daily were determined in the presence and absence of steady-state paroxetine 20 mg once daily.

Results: Duloxetine increased the maximum plasma concentration of desipramine 1.7-fold and the area under the concentration-time curve 2.9-fold. Paroxetine increased the maximum plasma concentration of duloxetine and the area under the concentration-time curve at steady state 1.6-fold. Reports of adverse events were similar whether duloxetine was administered alone or in combination with desipramine or paroxetine.

Conclusion: Duloxetine 60 mg twice daily is a moderately potent CYP2D6 inhibitor, intermediate between paroxetine and sertraline. The potent CYP2D6 inhibitor paroxetine has a moderate effect on duloxetine concentrations. The results of these 2 studies suggest that caution should be used when CYP2D6 substrates and inhibitors are coadministered with duloxetine.

Download full-text PDF

Source
http://dx.doi.org/10.1067/mcp.2003.28DOI Listing
March 2003
38 Reads

Publication Analysis

Top Keywords

potent cyp2d6
12
cyp2d6 inhibitor
12
duloxetine daily
12
duloxetine
12
plasma concentration
8
duloxetine pharmacokinetics
8
cytochrome p4502d6
8
concentration-time curve
8
maximum plasma
8
increased maximum
8
area concentration-time
8
cyp2d6
7
inhibitor
5
paroxetine
5
daily determined
4
steady-state pharmacokinetics
4
pharmacokinetics duloxetine
4
steady-state paroxetine
4
dailyresults duloxetine
4
duloxetine increased
4

Similar Publications